Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 6
---
 the growth and replication of diseased cells and stimulate innate immune cells to attack them. They have been used as standard
of care for hepatitis B and C and multiple sclerosis, and to a lesser extent, as treatment for certain cancers, including chronic myeloid
leukemia, cutaneous T-cell lymphoma, myeloma and non-Hodgkin’s lymphoma. However, the use of interferons has generally decreased
over the years due to serious adverse events (e.g., flu-like symptoms and dramatic weight loss) and introduction of new therapies
with higher efficacy, better safety profiles and more convenient administration although Alpha-interferon remains the treatment of choice
for some hematological conditions such as polycythemia. IL-2 activates T-cells and NK cells to attack diseased cells. IL-2 has been used
to treat select cancers, but due to its relatively poor safety profile, physicians often only resort to this therapy for the most advanced
settings.

Antibody therapy.
Antibodies exist in three formats: monoclonals (“mAbs”), oligo/polyclonal and antibody-drug conjugates. mAbs represent an
effective therapeutic modality and are important to the treatment paradigm of various diseases. Drug manufacturers have leveraged mAbs’
ability to induce an antibody-dependent cell-mediated cytotoxicity, or ADCC effect to develop better treatments that prolong survival
and quality of life of patients. In addition, mAbs designed to inhibit specific checkpoints in the immune system have overcome in vivo
immune suppression and the resulting immune responses have led to profound therapeutic benefit in some patients. However, the degree of
efficacy of these therapies is heavily reliant on the immune system of patients, many of whom are severely immuno-compromised. In addition,
mAbs are manufactured through a complex process that requires purification of cell products created from a cell line. Polyspecific antibodies,
for example bi-specific antibodies, are able to target more than one antigen. These are often used to bring and effector T cell in contact
with a target cell. Antibody drug conjugates are mAbs attached to a toxin, chemotherapy or radio therapy that delivers the cancer killing
payload directly to the cancer.

3

Dendritic Cell Therapies.
This approach is designed to indirectly stimulate a patient’s T-cells by leveraging the role of dendritic cells in presenting antigens
to T-cells. Cancer vaccines are the most common application of dendritic cells. FDA-approved dendritic cell therapies such